1. Home
  2. REGN vs CDNS Comparison

REGN vs CDNS Comparison

Compare REGN & CDNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • CDNS
  • Stock Information
  • Founded
  • REGN 1988
  • CDNS 1988
  • Country
  • REGN United States
  • CDNS United States
  • Employees
  • REGN N/A
  • CDNS N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • CDNS Computer Software: Prepackaged Software
  • Sector
  • REGN Health Care
  • CDNS Technology
  • Exchange
  • REGN Nasdaq
  • CDNS Nasdaq
  • Market Cap
  • REGN 63.4B
  • CDNS 64.1B
  • IPO Year
  • REGN 1991
  • CDNS 1987
  • Fundamental
  • Price
  • REGN $527.78
  • CDNS $305.78
  • Analyst Decision
  • REGN Buy
  • CDNS Buy
  • Analyst Count
  • REGN 23
  • CDNS 13
  • Target Price
  • REGN $907.39
  • CDNS $322.92
  • AVG Volume (30 Days)
  • REGN 1.3M
  • CDNS 2.0M
  • Earning Date
  • REGN 04-29-2025
  • CDNS 04-28-2025
  • Dividend Yield
  • REGN 0.33%
  • CDNS N/A
  • EPS Growth
  • REGN 16.49
  • CDNS 2.60
  • EPS
  • REGN 39.43
  • CDNS 3.94
  • Revenue
  • REGN $14,085,700,000.00
  • CDNS $4,874,527,000.00
  • Revenue This Year
  • REGN $2.38
  • CDNS $14.06
  • Revenue Next Year
  • REGN $7.65
  • CDNS $11.96
  • P/E Ratio
  • REGN $13.39
  • CDNS $77.61
  • Revenue Growth
  • REGN 7.52
  • CDNS 19.55
  • 52 Week Low
  • REGN $525.99
  • CDNS $221.56
  • 52 Week High
  • REGN $1,211.20
  • CDNS $328.99
  • Technical
  • Relative Strength Index (RSI)
  • REGN 35.08
  • CDNS 65.65
  • Support Level
  • REGN $520.50
  • CDNS $302.29
  • Resistance Level
  • REGN $615.61
  • CDNS $313.00
  • Average True Range (ATR)
  • REGN 22.65
  • CDNS 7.87
  • MACD
  • REGN -2.54
  • CDNS 2.22
  • Stochastic Oscillator
  • REGN 7.65
  • CDNS 88.17

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About CDNS Cadence Design Systems Inc.

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house semiconductor design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Share on Social Networks: